NCT00880412已完成2 期
A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase IIA Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 (40 and 80 mg Bid) as Adjunctive Therapy to Acetylcholinesterase Inhibitor Over a 3-month Period in Ambulatory Patients Suffering From Mild to Moderate Alzheimer's Disease (EHT 0202/002 Protocol)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Exonhit
- 入组人数
- 197
- 试验地点
- 12
- 主要终点
- incidence/frequency and severity of adverse events, relation to treatment start and drug exposure, drop-out rate, including reason for withdrawal, clinical examination, change from screening of biological safety parameters, vital signs, ECG and weight.
研究概览
简要总结
The objective of this 3-month study is to assess the safety and efficacy of EHT 0202 in addition to acetylcholinesterase inhibitor in patients suffering from Alzheimer's Disease.
详细描述
The aim of this pilot study is to assess the safety and tolerability profile of 2 doses of EHT 0202 (40 mg and 80 mg b.i.d) versus placebo in addition to a treatment with acetylcholinesterase inhibitor and its exploratory efficacy on cognition, behavior, activities of daily living, caregiver's burden and patient's global assessment, during a 3-month treatment period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 60 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ambulatory male or female patient, aged 60-90 years old included at screening, and living at home.
- •Patient having a clinical diagnosis of probable AD according to National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
- •Mild to moderate AD with a MMSE total score ≥ 12 and ≤ 24 at screening.
- •Written informed consent obtained from the patient or, if appropriate, from legal representative according to local laws and regulations. The caregiver will also have to sign a specific informed consent form regarding his/her participation in the study.
- •Patient treated for AD treatment with one AChEI (donepezil, galantamine, or rivastigmine), according to the recommended posology mentioned in the summary of product characteristics, for at least 3 months and with a stable dose for at least 2 months prior to screening. The dose should be kept unchanged throughout the study duration.
- •Patient with a cerebral CT-scan or cerebral MRI compatible with AD diagnosis, with no brain lesions that may be related to another diagnosis and that could be responsible for the current patient's condition (ex, but not limited to, non-AD dementia, brain injury, brain tumour, stroke, normal pressure hydrocephalus,...). A cerebral CT-scan or cerebral MRI has to be performed and results have to be available prior patient's randomization if the results of the brain imagery performed to settle the AD diagnosis are not available in the patient's file. Brain imaging has also to be performed if considered necessary by the investigator, such as in case of emerging neurological symptoms or in case of worsening of existing neurological symptoms.
- •Neurological exam without any particularities or without any specific focal signs likely to be related to other conditions than AD.
- •No contra-indication to AChEI treatment and absence of significant adverse events considered to be related to AChEI treatment at screening and randomisation.
- •Patient and patient's caregiver able to comply with study procedures, notably regarding the drug intake at the end of the meal which has to be supervised by the caregiver or another competent person.
排除标准
- •Diagnosis of vascular dementia according to NINDS-AIREN criteria, or other non-AD dementia, or CNS pathology (including but not limited to brain injury, brain tumour, stroke, normal pressure hydrocephalus, Parkinson's disease, epilepsy,multiple sclerosis,...) that may be responsible for dementia.
- •Clinically significant pathology and/or uncontrolled condition, including but not limited to cancer, infectious (like AIDS), gastro-intestinal, hepatic, renal, respiratory, endocrine(like diabetes mellitus, thyroiditis) pathology.
- •History or current clinically significant psychiatric pathology (including but not limited to psychotic disorders, bipolar disorder, personality disorders) that may interfere with study assessments.
- •Current major depressive disorder, either treated or not, associated with clinically significant symptoms.
- •Low blood level of vitamin B12, TSH levels out of normal range at screening.
- •Current forbidden medication intake or intake within 2 weeks prior to screening.
- •Recent history (within the past year prior to inclusion) or current cardiovascular pathology and/or symptoms considered as clinically significant, including but not limited to angina pectoris, uncontrolled arrhythmia, significant ECG abnormalities. Lifetime history of heart failure, myocardial infarction, severe and/or uncontrolled angina pectoris,and/or ventricular arrhythmia disqualifies the patient.
- •History or presence of clinically conditions that may interfere with product metabolism or with study assessments.
- •Systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 90 mmHg at screening and/or randomisation.
- •QTc interval (Bazett's correction) ≥ 430 msec for male and ≥ 450 msec for female at screening.
- •Laboratory values (biochemistry, haematology, urinalysis) considered as clinically significant and/or that may interfere with study assessments, according to the investigator.
- •ALAT, ASAT, ALP > 2.5 times the upper normal limit (UNL), total bilirubin > 1.5 UNL or history of significant liver pathology including hepatitis caused by drugs, HBV, HCV.
- •BUN, creatinin > 1.5 UNL.
- •Current or recent history of drug or alcohol abuse or dependence.
- •Patient not registered at "Sécurité Sociale".
- •Participation in another study within 1 month prior to screening and during the whole duration of the study.
研究组 & 干预措施
EHT 0202 40 mg bid
Experimental
study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
干预措施: EHT 0202 etazolate (Drug)
EHT 0202 80 mg bid
Experimental
study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
干预措施: EHT 0202 etazolate (Drug)
placebo bid
Placebo Comparator
study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
干预措施: Placebo (Drug)
结局指标
主要结局
incidence/frequency and severity of adverse events, relation to treatment start and drug exposure, drop-out rate, including reason for withdrawal, clinical examination, change from screening of biological safety parameters, vital signs, ECG and weight.
时间窗: all study visits
次要结局
- Assessment of cognition (ADAS-Cog, Neuropsychological Test Battery, MMSE), patient's global functioning (CDR-SB,CGI), patient's behaviour (NPI), daily living activities (ADCS-ADL) and caregiver's burden. Population PK of EHT 0202 and PK/PD profile.(at the end of the 3-month study treatment period)
研究者
研究点 (12)
Loading locations...
相似试验
尚未招募
2 期
HEM1036 Phase 2 Study in Low Anterior Resection SyndromeLARS - Low Anterior Resection SyndromeNCT05527301HEM Pharma Inc.67
已完成
2 期
Study of PH3 for the Prevention of Osteoporosis in Postmenopausal WomenOsteoporosisNCT00693667PhytoHealth Corporation92
招募中
不适用
A Study of EH002 Gene Therapy for Otoferlin Gene Mutation-mediated Hearing LossDFNB9Congenital Hearing LossHearing Loss, SensorineuralNCT06722170Yilai Shu24
已完成
2 期
Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty SurgeryPostoperative PainNCT02689258Heron Therapeutics277
已完成
2 期
RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSAObstructive Sleep ApneaNCT06146101Incannex Healthcare Ltd121